- SEK84.45m
- SEK73.87m
Brief: Alzinova Appoints Erik Kullgren As Permanent CFO
Brief: Alzinova Reports Positive Results From Phase 1B Extension Part Of Alz-101 Study
Brief: Alzinova Q3 Loss After Financial Items Widens To TSEK 4,151
Brief: Alzinova Appoints Tord Labuda As CEO
Brief: Maida Vale Capital Increases Holding In Alzinova
Brief: Alzinova Appoints Carol Routledge As Acting CEO
Brief: Alzinova’S Rights Issue Oversubscribed
Brief: New Positive Safety Review For Alzinova's Phase 1B Study
Brief: Alzinova Q1 Adj. EPS at SEK -0.11
Brief: Alzinova Q1 Net Sales Amounted To SEK 30,000
Brief: Alzinova Resolves On Rights Issue Of About SEK 34.4 Mln
Brief: Kristina Torfgard To Leave CEO Position At Alzinova
Brief: Alzinova Appoints Erik Kullgren As Interim CFO
Brief: Alzinova Proposes That No Dividends Are Paid For 2023
Brief: Alzinova Q4 Adj. EPS at SEK -0.11
Brief: Alzinova Confirms Positive Phase 1B Results With Alz-101 Against Alzheimer's
Brief: Alzinova's CFO Håkan Skogström To Retire Next Year
Brief: Alzinova: Positive Phase 1B Results With Vaccine Candidate Alz-101
Brief: Alzinova Q3 Loss After Financial Items Widens To SEK 3.5 Mln